有与无乳腺癌病史女性心脏代谢危险因素风险:Pathways心脏研究
该研究在Kaiser Permanente北加州医疗系统内识别2005至2013年诊断为浸润性乳腺癌的女性,按出生年份、种族和民族1:5匹配非癌对照,比较高血压、糖尿病和血脂异常累积发病率。乳腺癌幸存者糖尿病和高血压风险升高,且与化疗、左侧放疗、内分泌治疗及体重指数相关。
要点
- 乳腺癌幸存者2年高血压累积发病率为10.9%,对照为8.9%。
- 乳腺癌幸存者2年糖尿病累积发病率为2.1%,对照为1.7%。
- 接受化疗、左侧放疗或内分泌治疗的乳腺癌患者糖尿病风险仍较高。
核心结论
- KPNC的乳腺癌幸存者与无乳腺癌女性相比,糖尿病和高血压风险升高,且取决于所接受的治疗和体重指数。
- 未来研究应探索乳腺癌幸存者心脏代谢危险因素的预防策略。
研究设计与样本
- 研究在Kaiser Permanente北加州(KPNC)识别2005至2013年诊断的浸润性乳腺癌女性,并按出生年份、种族和民族1:5匹配非癌对照。
- 共纳入14,942例乳腺癌病例和74,702例匹配对照,平均年龄61.2岁,65%为非西班牙裔白人。
- 采用竞争风险模型估计高血压、糖尿病和血脂异常的累积发病率,并用Fine和Gray回归估计亚分布风险比(sHR),调整心血管疾病相关危险因素并按治疗和体重指数分层。
主要发现
- 乳腺癌病例2年高血压累积发病率为10.9%,对照为8.9%。
- 乳腺癌病例2年糖尿病累积发病率为2.1%,对照为1.7%;10年后糖尿病发病率仍较高(9.3% vs 8.8%)。
- 多变量模型中,病例糖尿病风险高于对照(sHR 1.16;95% CI 1.07至1.26)。
- 接受化疗(sHR 1.23;95% CI 1.11至1.38)、左侧放疗(sHR 1.29;95% CI 1.13至1.48)或内分泌治疗(sHR 1.23;95% CI 1.12至1.34)的病例糖尿病风险仍较高。
- 接受左侧放疗(sHR 1.11;95% CI 1.02至1.21)或内分泌治疗(sHR 1.10;95% CI 1.03至1.16)的病例高血压风险较高。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: The incidence of cardiometabolic risk factors in breast cancer (BC) survivors has not been well described. Thus, we compared risk of hypertension, diabetes, and dyslipidemia in women with and without BC. METHODS: Women with invasive BC diagnosed from 2005 to 2013 at Kaiser Permanente Northern California (KPNC) were identified and matched 1:5 to noncancer controls on birth year, race, and ethnicity. Cumulative incidence rates of hypertension, diabetes, and dyslipidemia were estimated with competing risk of overall death. Subdistribution hazard ratios (sHRs) were estimated by Fine and Gray regression, adjusted for cardiovascular disease-related risk factors, and stratified by treatment and body mass index (BMI). RESULTS: A total of 14,942 BC cases and 74,702 matched controls were identified with mean age 61.2 years and 65% non-Hispanic White. Compared with controls, BC cases had higher cumulative incidence rates of hypertension (10.9% v 8.9%) and diabetes (2.1% v 1.7%) after 2 years, with higher diabetes incidence persisting after 10 years (9.3% v 8.8%). In multivariable models, cases had higher risk of diabetes (sHR, 1.16; 95% CI, 1.07 to 1.26) versus controls. Cases treated with chemotherapy (sHR, 1.23; 95% CI, 1.11 to 1.38), left-sided radiation (sHR, 1.29; 95% CI, 1.13 to 1.48), or endocrine therapy (sHR, 1.23; 95% CI, 1.12 to 1.34) continued to have higher diabetes risk. Hypertension risk was higher for cases receiving left-sided radiation (sHR, 1.11; 95% CI, 1.02 to 1.21) or endocrine therapy (sHR, 1.10; 95% CI, 1.03 to 1.16). Normal-weight (BMI < 24.9 kg/m2) cases had higher risks overall and within treatment subgroups versus controls. CONCLUSION: BC survivors at KPNC experienced elevated risks of diabetes and hypertension compared with women without BC depending on treatments received and BMI. Future studies should examine strategies for cardiometabolic risk factor prevention in BC survivors.
引用
- Kwan ML, Cheng RK, Iribarren C, et al. Risk of Cardiometabolic Risk Factors in Women With and Without a History of Breast Cancer: The Pathways Heart Study. J Clin Oncol. 2022. PMID: 35025627. doi:10.1200/JCO.21.01738
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。